Biodacyna Ophthalmicum 0.3%, 3 mg/ml, Eye Drops, Solution
Amikacin
The medicine is intended for instillation into the eye, as recommended by a doctor.
Biodacyna Ophthalmicum 0.3% eye drops contain the aminoglycoside antibiotic amikacin.
Amikacin is a semi-synthetic antibiotic from the aminoglycoside group with a broad spectrum of activity. It exhibits strong bactericidal activity against most strains resistant to other aminoglycoside antibiotics (gentamicin, tobramycin, and kanamycin). It is active against Gram-negative and some Gram-positive bacteria.
The antibiotic is effective in treating eye infections caused by bacteria: Staphylococcus
aureus, Proteus spp., Escherichia coli, Serratia spp., Enterobacter spp., Klebsiella spp. and
Pseudomonas spp., including Pseudomonas aeruginosa.
Biodacyna Ophthalmicum 0.3% is used to treat bacterial eye infections: conjunctivitis, keratitis, blepharitis, and meibomian gland infection, as well as for the treatment of hordeolum.
The medicine is given prophylactically to patients preparing for eye surgery.
Before starting treatment with Biodacyna Ophthalmicum 0.3%, consult a doctor or pharmacist.
If the use of the medicine causes disturbing symptoms of eye irritation (itching, burning, or swelling of the eyelids), contact a doctor immediately.
Tell the doctor or pharmacist about all medicines the patient is currently taking or has recently taken, as well as any medicines the patient plans to take.
In severe infections caused by Pseudomonas aeruginosa, the doctor may recommend amikacin in the form of an injection solution and other eye drops.
When using Biodacyna Ophthalmicum 0.3% eye drops and another eye preparation, wait at least 15 minutes between administrations, so that the drop can spread over the cornea in an undiluted state.
If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a child, they should consult a doctor or pharmacist before using this medicine.
Symptoms of the disease and the occurrence of side effects may make it impossible to drive vehicles and operate machines.
The medicine contains 6.34 mg of phosphates in each milliliter of solution. In patients with severe damage to the transparent, anterior part of the eye (cornea), phosphates may, in very rare cases, cause corneal clouding during treatment due to calcium deposition.
The medicine contains 0.1 mg of benzalkonium chloride in each milliliter of solution. Benzalkonium chloride can be absorbed by soft contact lenses and change their color. Remove contact lenses before instillation and wait at least 15 minutes before reinserting.
In case of eye infection, wearing contact lenses is not recommended.
Benzalkonium chloride can also cause eye irritation, especially in people with dry eye syndrome or corneal disorders (the transparent layer at the front of the eye). If abnormal sensations occur in the eye, stinging, or pain in the eye after using the medicine, consult a doctor.
Always use this medicine exactly as your doctor or pharmacist has told you. If you are not sure, ask your doctor or pharmacist.
Instill 1-2 drops of the medicine 3 or 4 times a day into the conjunctival sac (by gently pulling down the lower eyelid) usually for 7 to 10 days, as recommended by the doctor.
Overdose may occur if the drops are used more frequently than 4 times a day.
This may cause an increase in side effects.
Do not stop using the medicine without consulting a doctor.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Side effects are very rare (less than 1 in 10,000 people). They usually do not require discontinuation of treatment.
Nonspecific conjunctivitis, burning sensation, itching, irritation, and hypersensitivity reactions with eyelid redness, itching, swelling may occur.
If after using Biodacyna Ophthalmicum 0.3% the patient experiences hypersensitivity reactions, discontinue the use of the medicine and consult a doctor immediately.
In patients with severe damage to the transparent, anterior part of the eye (cornea), phosphates may, in very rare cases, cause corneal clouding during treatment due to calcium deposition.
If you experience any side effects, including those not listed in this leaflet, tell your doctor or pharmacist. Side effects can be reported directly to the Department of Pharmacovigilance of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products
Al. Jerozolimskie 181C
02-222 Warsaw
Phone: +48 22 49 21 301
Fax: +48 22 49 21 309
Website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
Reporting side effects will help to gather more information on the safety of this medicine.
Keep the medicine out of the sight and reach of children.
Store in a temperature below 25°C. Protect from light.
The medicine is suitable for use within 28 days of first opening the bottle.
Discard the medicine after completion of treatment.
Do not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the month stated.
The inscription on the packaging after the abbreviation EXP means the expiry date, and after the abbreviation Lot means the batch number.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
LDPE bottle with LDPE dropper and HDPE cap in a cardboard box.
The pack contains 5 ml of solution.
Zakłady Farmaceutyczne POLPHARMA S.A.
ul. Pelplińska 19, 83-200 Starogard Gdański
phone: +48 22 364 61 01
Jadran-Galenski Laboratorij d.d.
Svilno 20, 51000 Rijeka
Croatia
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.